The Roles of Endogenous Opioids in Placebo and Nocebo Effects: From Pain to Performance to Prozac

Overview

Journal Adv Neurobiol

Publisher Springer

Date 2024 Jun 14

PMID 38874724

Authors

Patrick L Kerr

John M Gregg

Affiliations

Soon will be listed here.

Abstract

Placebo and nocebo effects have been well documented for nearly two centuries. However, research has only relatively recently begun to explicate the neurobiological underpinnings of these phenomena. Similarly, research on the broader social implications of placebo/nocebo effects, especially within healthcare delivery settings, is in a nascent stage. Biological and psychosocial outcomes of placebo/nocebo effects are of equal relevance. A common pathway for such outcomes is the endogenous opioid system. This chapter describes the history of placebo/nocebo in medicine; delineates the current state of the literature related to placebo/nocebo in relation to pain modulation; summarizes research findings related to human performance in sports and exercise; discusses the implications of placebo/nocebo effects among diverse patient populations; and describes placebo/nocebo influences in research related to psychopharmacology, including the relevance of endogenous opioids to new lines of research on antidepressant pharmacotherapies.

References

Amanzio M, Benedetti F . Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1998; 19(1):484-94. PMC: 6782391. View

Amanzio M, Corazzini L, Vase L, Benedetti F . A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009; 146(3):261-269. DOI: 10.1016/j.pain.2009.07.010. View

Andersen S, Petersen M, Svendsen A, Gazerani P . Pressure pain thresholds assessed over temporalis, masseter, and frontalis muscles in healthy individuals, patients with tension-type headache, and those with migraine--a systematic review. Pain. 2015; 156(8):1409-1423. DOI: 10.1097/j.pain.0000000000000219. View

Apkarian A, Baliki M, Geha P . Towards a theory of chronic pain. Prog Neurobiol. 2008; 87(2):81-97. PMC: 2650821. DOI: 10.1016/j.pneurobio.2008.09.018. View

Araldi D, Ferrari L, Levine J . Repeated Mu-Opioid Exposure Induces a Novel Form of the Hyperalgesic Priming Model for Transition to Chronic Pain. J Neurosci. 2015; 35(36):12502-17. PMC: 4563038. DOI: 10.1523/JNEUROSCI.1673-15.2015. View

Araldi D, Ferrari L, Levine J . Hyperalgesic priming (type II) induced by repeated opioid exposure: maintenance mechanisms. Pain. 2017; 158(7):1204-1216. PMC: 5474187. DOI: 10.1097/j.pain.0000000000000898. View

Attal N, Kayser V, Jazat F, Guilbaud G . Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat. Brain Res. 1989; 494(2):276-84. DOI: 10.1016/0006-8993(89)90596-9. View

Austin P, Kim C, Perera C, Moalem-Taylor G . Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. Pain. 2012; 153(9):1916-1931. DOI: 10.1016/j.pain.2012.06.005. View

Baliki M, Apkarian A . Nociception, Pain, Negative Moods, and Behavior Selection. Neuron. 2015; 87(3):474-91. PMC: 4529956. DOI: 10.1016/j.neuron.2015.06.005. View

10.

Ballantyne J . The brain on opioids. Pain. 2018; 159 Suppl 1:S24-S30. DOI: 10.1097/j.pain.0000000000001270. View

11.

Ballantyne J, Sullivan M . Discovery of endogenous opioid systems: what it has meant for the clinician's understanding of pain and its treatment. Pain. 2017; 158(12):2290-2300. DOI: 10.1097/j.pain.0000000000001043. View

12.

Bannister K, Bee L, Dickenson A . Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009; 6(4):703-12. PMC: 5084291. DOI: 10.1016/j.nurt.2009.07.009. View

13.

Bannister K, Patel R, Goncalves L, Townson L, Dickenson A . Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations. Pain. 2015; 156(9):1803-1811. DOI: 10.1097/j.pain.0000000000000240. View

14.

Bee L, Dickenson A . Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain. 2008; 140(1):209-223. DOI: 10.1016/j.pain.2008.08.008. View

15.

BEECHER H . Surgery as placebo. A quantitative study of bias. JAMA. 1961; 176:1102-7. DOI: 10.1001/jama.1961.63040260007008. View

16.

Bennett G, Xie Y . A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988; 33(1):87-107. DOI: 10.1016/0304-3959(88)90209-6. View

17.

Benedetti F, Amanzio M, Vighetti S, Asteggiano G . The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci. 2006; 26(46):12014-22. PMC: 6674855. DOI: 10.1523/JNEUROSCI.2947-06.2006. View

18.

Benedetti F, Amanzio M, Rosato R, Blanchard C . Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011; 17(10):1228-30. DOI: 10.1038/nm.2435. View

19.

Benedetti F, Thoen W, Blanchard C, Vighetti S, Arduino C . Pain as a reward: changing the meaning of pain from negative to positive co-activates opioid and cannabinoid systems. Pain. 2012; 154(3):361-367. DOI: 10.1016/j.pain.2012.11.007. View

20.

Birklein F, Ibrahim A, Schlereth T, Kingery W . The Rodent Tibia Fracture Model: A Critical Review and Comparison With the Complex Regional Pain Syndrome Literature. J Pain. 2018; 19(10):1102.e1-1102.e19. PMC: 6163066. DOI: 10.1016/j.jpain.2018.03.018. View